Lidex NGN Special Precautions

Because of the potential hazards of nephrotoxicity and ototoxicity of Neomycin, prolonged use or use of large amounts of this product should be avoided in the treatment of skin conditions following extensive burns, trophic ulceration and other conditions where absorption of Neomycin is possible.
In the presence of viral or fungal infection, the use of an appropriate agent should be instituted. If a favourable response does not occur promptly Fluocinonide, Nyomycin sulfate, gramicidin and Nystatin (Lidex NGN) Emollient Cream should be discontinued until the infection has been adequately controlled.
As with any antibiotic preparation, prolonged use may lead to overgrowth of non-susceptible and resistant organisms. Should this occur, other suitable antimicrobial therapy must be instituted.
Prolonged use of topical corticosteroid products may produce atrophy of the skin. When used on the face, this may occur even with short term use. Significant systemic absorption may result when steroids are applied over large areas of the body, even when occlusion is not used.
Administration of topical corticosteroids to children should be limited to a short period of time and to the smallest amount of product compatible with an effective therapeutic regimen.
This preparation is not intended for ophthalmic use.
Topical corticosteroids should be used with caution on lesions close to the eye.
It is recommended that Fluocinonide, Neomycin sulfate, gramicidin and Nystatin (Lidex NGN) Emollient Cream not be used under occlusive dressing.
Tight-fitting diapers or plastic pants on a child may also function as an occlusive dressing and increase absorption of topical corticosteroids by the underlying skin.
Patients (particularly children) receiving a large dose of topical corticosteroid applied to a large surface area or under an occlusive dressing should be evaluated for evidence of hypothalmic-pituitary-adrenal (HPA) axis suppression. If HPA axis suppression is noted, the dose should be reduced or gradually discontinued.
In laboratory animals, increases in incidences of fetal abnormalities have been associated with exposure of gestating females to topical corticosteroids, in some cases at rather low dosage levels. Although topical corticosteroids have been reported to have an adverse effects on human pregnancy, the safety of their use in pregnant women has not been established absolutely. Therefore, drugs of this class should not be used extensively on pregnant patients, in large amounts or for prolonged periods of time, especially during the first three months of pregnancy.